Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.63)
# 3,468
Out of 5,115 analysts
18
Total ratings
37.5%
Success rate
0.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $17.24 | +306.03% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $4.79 | +171.40% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $150 → $250 | $2.80 | +8,828.57% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $5.97 | +905.03% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $6.95 | +763.31% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $2.20 | +354.55% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $2.41 | +480.91% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.48 | +440.54% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $0.23 | +52,508.51% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $12.18 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.70 | +155.32% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $5.58 | +177,419,254.84% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.98 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.02 | +396.69% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $17.24
Upside: +306.03%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $4.79
Upside: +171.40%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150 → $250
Current: $2.80
Upside: +8,828.57%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $5.97
Upside: +905.03%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $6.95
Upside: +763.31%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.20
Upside: +354.55%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $2.41
Upside: +480.91%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.48
Upside: +440.54%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.23
Upside: +52,508.51%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.18
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $4.70
Upside: +155.32%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $5.58
Upside: +177,419,254.84%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $35.98
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $3.02
Upside: +396.69%